GrippeCanadaV3, Main, Exploration, bibRecord, 000009

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.

Identifieur interne : 000009 ( Main/Exploration ); précédent : 000008; suivant : 000010

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.

Auteurs : Yacine Abed ; Clément Fage ; Patrick Lagüe ; Julie Carbonneau ; Jesse Papenburg ; Donald C. Vinh ; Guy Boivin

Source :

Emerging infectious diseases [ 1080-6059 ] ; 2019.

RBID : pubmed:30882323

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Analyse de séquence d'ADN, Antienzymes (pharmacologie), Antienzymes (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Canada (épidémiologie), Femelle, Glycoprotéine hémagglutinine du virus influenza (génétique), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Mutation, Protéines virales (antagonistes et inhibiteurs), Protéines virales (génétique), Relation dose-effet des médicaments, Résistance virale aux médicaments, Sialidase (antagonistes et inhibiteurs), Sialidase (génétique), Tests de sensibilité microbienne, Virus influenza B (), Virus influenza B (enzymologie), Virus influenza B (génétique).
MESH :
- antagonistes et inhibiteurs : Protéines virales, Sialidase.
- enzymologie : Virus influenza B.
- génétique : Glycoprotéine hémagglutinine du virus influenza, Protéines virales, Sialidase, Virus influenza B.
- pharmacologie : Antienzymes, Antiviraux.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux.
- virologie : Grippe humaine.
- épidémiologie : Canada, Grippe humaine.
- Adulte d'âge moyen, Analyse de séquence d'ADN, Femelle, Humains, Mutation, Relation dose-effet des médicaments, Résistance virale aux médicaments, Tests de sensibilité microbienne, Virus influenza B.
Wicri :
- geographic : Canada.

English descriptors

KwdEn :
- Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Canada (epidemiology), Dose-Response Relationship, Drug, Drug Resistance, Viral, Enzyme Inhibitors (pharmacology), Enzyme Inhibitors (therapeutic use), Female, Hemagglutinin Glycoproteins, Influenza Virus (genetics), Humans, Influenza B virus (classification), Influenza B virus (drug effects), Influenza B virus (enzymology), Influenza B virus (genetics), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (virology), Microbial Sensitivity Tests, Middle Aged, Mutation, Neuraminidase (antagonists & inhibitors), Neuraminidase (genetics), Sequence Analysis, DNA, Viral Proteins (antagonists & inhibitors), Viral Proteins (genetics).
MESH :
- chemical , antagonists & inhibitors : Neuraminidase, Viral Proteins.
- chemical , genetics : Hemagglutinin Glycoproteins, Influenza Virus, Neuraminidase, Viral Proteins.
- chemical , pharmacology : Antiviral Agents, Enzyme Inhibitors.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors.
- geographic , epidemiology : Canada.
- classification : Influenza B virus.
- drug effects : Influenza B virus.
- drug therapy : Influenza, Human.
- enzymology : Influenza B virus.
- epidemiology : Influenza, Human.
- genetics : Influenza B virus.
- virology : Influenza, Human.
- Dose-Response Relationship, Drug, Drug Resistance, Viral, Female, Humans, Microbial Sensitivity Tests, Middle Aged, Mutation, Sequence Analysis, DNA.

Abstract

We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.

DOI: 10.3201/eid2504.181554
PubMed: 30882323

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000017
to stream Main, to step Curation: 000017

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.</title>
<author><name sortKey="Abed, Yacine" sort="Abed, Yacine" uniqKey="Abed Y" first="Yacine" last="Abed">Yacine Abed</name>
</author>
<author><name sortKey="Fage, Clement" sort="Fage, Clement" uniqKey="Fage C" first="Clément" last="Fage">Clément Fage</name>
</author>
<author><name sortKey="Lague, Patrick" sort="Lague, Patrick" uniqKey="Lague P" first="Patrick" last="Lagüe">Patrick Lagüe</name>
</author>
<author><name sortKey="Carbonneau, Julie" sort="Carbonneau, Julie" uniqKey="Carbonneau J" first="Julie" last="Carbonneau">Julie Carbonneau</name>
</author>
<author><name sortKey="Papenburg, Jesse" sort="Papenburg, Jesse" uniqKey="Papenburg J" first="Jesse" last="Papenburg">Jesse Papenburg</name>
</author>
<author><name sortKey="Vinh, Donald C" sort="Vinh, Donald C" uniqKey="Vinh D" first="Donald C" last="Vinh">Donald C. Vinh</name>
</author>
<author><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30882323</idno>
<idno type="pmid">30882323</idno>
<idno type="doi">10.3201/eid2504.181554</idno>
<idno type="wicri:Area/Main/Corpus">000017</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000017</idno>
<idno type="wicri:Area/Main/Curation">000017</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000017</idno>
<idno type="wicri:Area/Main/Exploration">000017</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.</title>
<author><name sortKey="Abed, Yacine" sort="Abed, Yacine" uniqKey="Abed Y" first="Yacine" last="Abed">Yacine Abed</name>
</author>
<author><name sortKey="Fage, Clement" sort="Fage, Clement" uniqKey="Fage C" first="Clément" last="Fage">Clément Fage</name>
</author>
<author><name sortKey="Lague, Patrick" sort="Lague, Patrick" uniqKey="Lague P" first="Patrick" last="Lagüe">Patrick Lagüe</name>
</author>
<author><name sortKey="Carbonneau, Julie" sort="Carbonneau, Julie" uniqKey="Carbonneau J" first="Julie" last="Carbonneau">Julie Carbonneau</name>
</author>
<author><name sortKey="Papenburg, Jesse" sort="Papenburg, Jesse" uniqKey="Papenburg J" first="Jesse" last="Papenburg">Jesse Papenburg</name>
</author>
<author><name sortKey="Vinh, Donald C" sort="Vinh, Donald C" uniqKey="Vinh D" first="Donald C" last="Vinh">Donald C. Vinh</name>
</author>
<author><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="eISSN">1080-6059</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Canada (epidemiology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Resistance, Viral</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Female</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Humans</term>
<term>Influenza B virus (classification)</term>
<term>Influenza B virus (drug effects)</term>
<term>Influenza B virus (enzymology)</term>
<term>Influenza B virus (genetics)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (virology)</term>
<term>Microbial Sensitivity Tests</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Neuraminidase (genetics)</term>
<term>Sequence Analysis, DNA</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Viral Proteins (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Analyse de séquence d'ADN</term>
<term>Antienzymes (pharmacologie)</term>
<term>Antienzymes (usage thérapeutique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Canada (épidémiologie)</term>
<term>Femelle</term>
<term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Mutation</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Protéines virales (génétique)</term>
<term>Relation dose-effet des médicaments</term>
<term>Résistance virale aux médicaments</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
<term>Sialidase (génétique)</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus influenza B ()</term>
<term>Virus influenza B (enzymologie)</term>
<term>Virus influenza B (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Neuraminidase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Protéines virales</term>
<term>Sialidase</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term>
<term>Drug Resistance, Viral</term>
<term>Female</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
<term>Middle Aged</term>
<term>Mutation</term>
<term>Sequence Analysis, DNA</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Analyse de séquence d'ADN</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mutation</term>
<term>Relation dose-effet des médicaments</term>
<term>Résistance virale aux médicaments</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30882323</PMID>
<DateCompleted><Year>2019</Year>
<Month>12</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1080-6059</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>4</Issue>
<PubDate><Year>2019</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.</ArticleTitle>
<Pagination><MedlinePgn>838-840</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3201/eid2504.181554</ELocationID>
<Abstract><AbstractText>We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abed</LastName>
<ForeName>Yacine</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fage</LastName>
<ForeName>Clément</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lagüe</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Carbonneau</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Papenburg</LastName>
<ForeName>Jesse</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vinh</LastName>
<ForeName>Donald C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Boivin</LastName>
<ForeName>Guy</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="C541223">NA protein, influenza B virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Canada</Keyword>
<Keyword MajorTopicYN="Y">Gly407Ser</Keyword>
<Keyword MajorTopicYN="Y">influenza</Keyword>
<Keyword MajorTopicYN="Y">influenza B</Keyword>
<Keyword MajorTopicYN="Y">neuraminidase</Keyword>
<Keyword MajorTopicYN="Y">oseltamivir</Keyword>
<Keyword MajorTopicYN="Y">peramivir</Keyword>
<Keyword MajorTopicYN="Y">resistance</Keyword>
<Keyword MajorTopicYN="Y">viruses</Keyword>
<Keyword MajorTopicYN="Y">zanamivir</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>12</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30882323</ArticleId>
<ArticleId IdType="doi">10.3201/eid2504.181554</ArticleId>
<ArticleId IdType="pmc">PMC6433030</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antivir Ther. 2006;11(8):971-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17302366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2011 Nov 4;86(45):497-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22128380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proteins. 1992 Nov;14(3):327-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1438172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2017 May 18;4(3):ofx105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28852674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2018 Feb;23(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29409570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Sep;58(9):5220-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24957832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Aug 15;8(8):e71401</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23977037</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 May;98(2):174-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23523943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2007 Apr 4;297(13):1435-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17405969</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Abed, Yacine" sort="Abed, Yacine" uniqKey="Abed Y" first="Yacine" last="Abed">Yacine Abed</name>
<name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name>
<name sortKey="Carbonneau, Julie" sort="Carbonneau, Julie" uniqKey="Carbonneau J" first="Julie" last="Carbonneau">Julie Carbonneau</name>
<name sortKey="Fage, Clement" sort="Fage, Clement" uniqKey="Fage C" first="Clément" last="Fage">Clément Fage</name>
<name sortKey="Lague, Patrick" sort="Lague, Patrick" uniqKey="Lague P" first="Patrick" last="Lagüe">Patrick Lagüe</name>
<name sortKey="Papenburg, Jesse" sort="Papenburg, Jesse" uniqKey="Papenburg J" first="Jesse" last="Papenburg">Jesse Papenburg</name>
<name sortKey="Vinh, Donald C" sort="Vinh, Donald C" uniqKey="Vinh D" first="Donald C" last="Vinh">Donald C. Vinh</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000009 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000009 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30882323
   |texte=   Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30882323" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki